Survivin-miRNA-loaded nanoparticles as auxiliary tools for radiation therapy: preparation, characterisation, drug release, cytotoxicity and therapeutic effect on colorectal cancer cells

References

• Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8(1)61–70
   PubMed Web of Science ®Google Scholar
• Arnedo A, Irache JM, Merodio M, Espuelas Millán MS. Albumin NP improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Controlled Release 2004; 94(1)217–27
   PubMed Web of Science ®Google Scholar
• Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N. Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000; 91(11)1204–9
   PubMedGoogle Scholar
• Basarkar A, Devineni D, Palaniappan R, Singh J. Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic NP for controlled delivery of plasmid DNA. Int J Pharm 2007; 343(1–2)247–54
   PubMedGoogle Scholar
• Boulaiz H, Marchal JA, Prados J, Melguizo C, Aránega A. Non-viral and viral vectors for gene therapy. Cell Mol Biol (Noisy-le-grand) 2005; 51(1)3–22
   PubMed Web of Science ®Google Scholar
• Capalbo G, Rodel C, Stauber RH, Knauer SK, Bache M, Kappler M, Rödel F. The role of survivin for radiation therapy: Prognostic and predictive factor and therapeutic target. Strahlenther Onkol 2007; 183(11)593–99
   PubMedGoogle Scholar
• Gardlik R, Palffy R, Hodosy J, Lukács J, Turna J, Celec P. Vectors and delivery systems in gene therapy. Med Sci Monit 2005; 11(4)RA110–121
   PubMed Web of Science ®Google Scholar
• Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Controlled Release 1999; 60(2–3)149–60
   PubMed Web of Science ®Google Scholar
• Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010; 624: 25–37
   PubMedGoogle Scholar
• Hunter AC. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv Drug Delivery Rev 2006; 58(14)1523–31
   PubMed Web of Science ®Google Scholar
• Kratz F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and NP. J Controlled Release 2008; 132(3)171–83
   PubMed Web of Science ®Google Scholar
• Kreuter J. NP–a historical perspective. Int J Pharm 2007; 331(1)1–10
   PubMed Web of Science ®Google Scholar
• Kufleitner J, Wagner S, Worek F, von Briesen H, Kreuter J. Adsorption of obidoxime onto human serum albumin NP: Drug loading, particle size and drug release. J Microencapsulation 2010; 27(6)506–13
   PubMed Web of Science ®Google Scholar
• Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N, Faust S, Vogel V. Human serum albumin (HSA) NP: Reproducibility of preparation process and kinetics of enzymatic degradation. Int J Pharm 2008; 347(1–2)109–17
   PubMed Web of Science ®Google Scholar
• Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. Optimization of the preparation process for human serum albumin (HSA) NP. Int J Pharm 2003; 257(1–2)169–80
   PubMed Web of Science ®Google Scholar
• Lladser A, Sanhueza C, Kiessling R, Quest AF. Is survivin the potential Achilles’ heel of cancer?. Adv Cancer Res 2011; 111: 1–37
   Google Scholar
• Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189–207
   PubMedGoogle Scholar
• Mo Y, Barnett ME, Takemoto D, Davidson H, Kompella UB. Human serum albumin NP for efficient delivery of Cu, Zn superoxide dismutase gene. Mol Vision 2007; 13: 746–57
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Takakura Y, Hashida M. Theoretical considerations involving the pharmacokinetics of plasmid DNA. Adv Drug Delivery Rev 2005; 57(5)675–88
   PubMedGoogle Scholar
• Niu X, Zou W, Liu C, Zhang N, Fu C. Modified nanoprecipitation method to fabricate DNA-loaded PLGA NP. Drug Dev Ind Pharm 2009; 35(11)1375–83
   PubMed Web of Science ®Google Scholar
• Reichert S, Rödel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, Kaina B, Rödel F. Survivin inhibition and DNA double-strand break repair: A molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 2011; 101(1)51–8
   PubMedGoogle Scholar
• Rhaese S, von Briesen H, Rübsamen-Waigmann H, Kreuter J, Langer K. Human serum albumin-polyethylenimine NP for gene delivery. J Controlled Release 2003; 92(1–2)199–208
   PubMed Web of Science ®Google Scholar
• Rödel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rödel C. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65(11)4881–7
   PubMedGoogle Scholar
• Rödel F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T, Fulda S, Rödel C. The role of survivin for radiation oncology: Moving beyond apoptosis inhibition. Curr Med Chem 2011; 18(2)191–9
   PubMedGoogle Scholar
• Steinhauser I, Langer K, Strebhardt K, Spänkuch B. Uptake of plasmid-loaded NP in breast cancer cells and effect on Plk1 expression. J Drug Target 2009; 17(8)627–37
   PubMed Web of Science ®Google Scholar
• Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J, Jr, Schwartz D, et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin NP. Biomaterials 2009; 31(8)2388–98
   PubMedGoogle Scholar
• Weber C, Reiss S, Langer K. Preparation of surface modified protein NP by introduction of sulfhydryl groups. Int J Pharm 2000; 211(1–2)67–78
   PubMedGoogle Scholar
• Yang Y, Gao Y, Chen L, Huang Y, Li Y. Downregulation of survivin expression and enhanced chemosensitivity of MCF-7 cells to adriamycin by PDMAE/survivin shRNA complex NP. Int J Pharm 2010; 405(1–2)188–95
   PubMedGoogle Scholar
• Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Büchel C, von Briesen H, Kreuter J. Albumin NP targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Controlled Release 2009; 137(1)78–86
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang G, Lin X, Chatzinikolaidou M, Jennissen HP, Laub M, Uludağ H. Polyethylenimine-coated albumin NP for BMP-2 delivery. Biotechnol Progr 2008; 24(4)945–56
   PubMedGoogle Scholar